Cargando…

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

BACKGROUND: Solid tumor hypoxic conditions prevent the generation of reactive oxygen species (ROS) and the formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, which ultimately contributes to radiotherapy (RT) resistance. Recently, there have been significant technical advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haijun, Jia, Dianlong, Yuan, Dandan, Yin, Xiaolei, Yuan, Fengjiao, Wang, Feifei, Shi, Wenna, Li, Hui, Zhu, Li-Min, Fan, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120847/
https://www.ncbi.nlm.nih.gov/pubmed/33985511
http://dx.doi.org/10.1186/s12951-021-00885-6
_version_ 1783692194835595264
author Wang, Haijun
Jia, Dianlong
Yuan, Dandan
Yin, Xiaolei
Yuan, Fengjiao
Wang, Feifei
Shi, Wenna
Li, Hui
Zhu, Li-Min
Fan, Qing
author_facet Wang, Haijun
Jia, Dianlong
Yuan, Dandan
Yin, Xiaolei
Yuan, Fengjiao
Wang, Feifei
Shi, Wenna
Li, Hui
Zhu, Li-Min
Fan, Qing
author_sort Wang, Haijun
collection PubMed
description BACKGROUND: Solid tumor hypoxic conditions prevent the generation of reactive oxygen species (ROS) and the formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, which ultimately contributes to radiotherapy (RT) resistance. Recently, there have been significant technical advances in nanomedicine to reduce hypoxia by facilitating in situ O(2) production, which in turn serves as a “radiosensitizer” to increase the sensitivity of tumor cells to ionizing radiation. However, off-target damage to the tumor-surrounding healthy tissue by high-energy radiation is often unavoidable, and tumor cells that are further away from the focal point of ionizing radiation may avoid damage. Therefore, there is an urgent need to develop an intelligent targeted nanoplatform to enable precise enhanced RT-induced DNA damage and combined therapy. RESULTS: Human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (Z(Her2)) mediated cisplatin-loaded mesoporous polydopamine/MnO(2)/polydopamine nanoparticles (Pt@mPDA/MnO(2)/PDA-Z(Her2) NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumors is reported. These NPs are biodegradable under a simulated tumor microenvironment, resulting in accelerated cisplatin release, as well as localized production of O(2). Z(Her2), produced using the E. coli expression system, endowed NPs with Her2-dependent binding ability in Her2-positive SKOV-3 cells. An in vivo MRI revealed obvious T(1) contrast enhancement at the tumor site. Moreover, these NPs achieved efficient tumor homing and penetration via the efficient internalization and penetrability of Z(Her2). These NPs exhibited excellent inhibition of tumor growth with X-ray irradiation. An immunofluorescence assay showed that these NPs significantly reduced the expression of HIF-1α and improved ROS levels, resulting in radiosensitization. CONCLUSIONS: The nanocarriers described in the present study integrated Her2 targeting, diagnosis and RT sensitization into a single platform, thus providing a novel approach for translational tumor theranostics. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00885-6.
format Online
Article
Text
id pubmed-8120847
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81208472021-05-17 Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy Wang, Haijun Jia, Dianlong Yuan, Dandan Yin, Xiaolei Yuan, Fengjiao Wang, Feifei Shi, Wenna Li, Hui Zhu, Li-Min Fan, Qing J Nanobiotechnology Research BACKGROUND: Solid tumor hypoxic conditions prevent the generation of reactive oxygen species (ROS) and the formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, which ultimately contributes to radiotherapy (RT) resistance. Recently, there have been significant technical advances in nanomedicine to reduce hypoxia by facilitating in situ O(2) production, which in turn serves as a “radiosensitizer” to increase the sensitivity of tumor cells to ionizing radiation. However, off-target damage to the tumor-surrounding healthy tissue by high-energy radiation is often unavoidable, and tumor cells that are further away from the focal point of ionizing radiation may avoid damage. Therefore, there is an urgent need to develop an intelligent targeted nanoplatform to enable precise enhanced RT-induced DNA damage and combined therapy. RESULTS: Human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (Z(Her2)) mediated cisplatin-loaded mesoporous polydopamine/MnO(2)/polydopamine nanoparticles (Pt@mPDA/MnO(2)/PDA-Z(Her2) NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumors is reported. These NPs are biodegradable under a simulated tumor microenvironment, resulting in accelerated cisplatin release, as well as localized production of O(2). Z(Her2), produced using the E. coli expression system, endowed NPs with Her2-dependent binding ability in Her2-positive SKOV-3 cells. An in vivo MRI revealed obvious T(1) contrast enhancement at the tumor site. Moreover, these NPs achieved efficient tumor homing and penetration via the efficient internalization and penetrability of Z(Her2). These NPs exhibited excellent inhibition of tumor growth with X-ray irradiation. An immunofluorescence assay showed that these NPs significantly reduced the expression of HIF-1α and improved ROS levels, resulting in radiosensitization. CONCLUSIONS: The nanocarriers described in the present study integrated Her2 targeting, diagnosis and RT sensitization into a single platform, thus providing a novel approach for translational tumor theranostics. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00885-6. BioMed Central 2021-05-13 /pmc/articles/PMC8120847/ /pubmed/33985511 http://dx.doi.org/10.1186/s12951-021-00885-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Haijun
Jia, Dianlong
Yuan, Dandan
Yin, Xiaolei
Yuan, Fengjiao
Wang, Feifei
Shi, Wenna
Li, Hui
Zhu, Li-Min
Fan, Qing
Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
title Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
title_full Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
title_fullStr Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
title_full_unstemmed Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
title_short Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
title_sort dimeric her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120847/
https://www.ncbi.nlm.nih.gov/pubmed/33985511
http://dx.doi.org/10.1186/s12951-021-00885-6
work_keys_str_mv AT wanghaijun dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT jiadianlong dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT yuandandan dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT yinxiaolei dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT yuanfengjiao dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT wangfeifei dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT shiwenna dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT lihui dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT zhulimin dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy
AT fanqing dimericher2specificaffibodymediatedcisplatinloadednanoparticlesfortumorenhancedchemoradiotherapy